SOURCE: Implant Sciences Corporation

Implant Sciences Corporation

December 10, 2012 07:00 ET

Implant Sciences QS-B220 Trace Detection System Gains Further Traction in the European Airport Security Market

WILMINGTON, MA--(Marketwire - Dec 10, 2012) -  Implant Sciences Corporation (OTCQB: IMSC), a high technology supplier of systems and sensors for homeland security and defense markets, today announced that it has sold its Quantum Sniffer™ QS-B220 desktop explosives and drugs trace detector to a new customer in Europe. The unit will be used for airport security at a major international airport in Europe.

"Designed to meet the requirements of aviation security professionals, our desktop trace detector is gaining increasing acceptance and traction in global markets. As we continue to grow our distribution channel, we look forward to demonstrating its advantages in increasing numbers of procurements," stated Implant Sciences' President and CEO, Glenn D. Bolduc.

"The QS-B220 provides an effective method for screening passengers without concerns about radiation and privacy. This and the ability to adapt the easy-to-use touch-screen interface to the local language were important factors in Implant Sciences winning this order from a new customer through a new distributor," added Dr. Darryl Jones, Implant Sciences' Vice President of Sales and Marketing.

About the Quantum Sniffer™ QS-B220 Desktop Explosives Trace Detector

The Quantum Sniffer QS-B220 uses Ion Mobility Spectrometry (IMS) to rapidly detect and identify trace amounts of a wide variety of military, commercial, and homemade explosives, as well as drugs. Featuring a radioactive material-free design, push-button maintenance and diagnostics, and internal automatic self-calibration, the QS-B220 brings new levels of performance and convenience to desktop trace detection users with unsurpassed ease of use.

About Implant Sciences

Implant Sciences develops, manufactures and sells sophisticated sensors and systems for Security, Safety, and Defense (SS&D) markets. The Company has developed proprietary technologies used in its commercial explosive and narcotics trace detection systems which ship to a growing number of locations domestically and internationally. Implant Sciences' QS-H150 portable explosives trace detector has received Qualified Anti-Terrorism Technology Designation and the Company's QS-B220 desktop explosives and drugs trace detector has received a Developmental Testing & Evaluation (DT&E) Designation by the U.S. Department of Homeland Security under the Support Anti-terrorism by Fostering Effective Technology Act of 2002 (the SAFETY Act). For further details on the Company and its products, please visit the Company's website at www.implantsciences.com.

Safe Harbor Statement

This press release may contain certain "forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause the Company's actual results to differ materially from the forward-looking statements. Such risks and uncertainties include, but are not limited to, the risks that our explosives detection products and technologies (including any new products we may develop) may not be accepted by the Transportation Security Administration or by other U.S. or foreign government and law enforcement agencies or commercial consumers of security products; economic, political and other risks associated with international sales and operations could adversely affect our sales; our business is subject to intense competition and rapid technological change; the risks that our markets are subject to technological change and that our success depends on our ability to develop and introduce new products; and other risks and uncertainties described in our filings with the Securities and Exchange Commission, including its most recent Forms 10-K, 10-Q and 8-K. Such statements are based on management's current expectations and assumptions which could differ materially from the forward-looking statements.

Contact Information

  • Contact:

    Implant Sciences Corporation
    Company Contact:
    Glenn Bolduc
    CEO
    978-752-1700
    Email Contact

    or

    Investor Contact:
    Laurel Moody
    646-810-0608
    Email Contact